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Abstract
Introduction Mutations in BRCA1, BRCA2, ATM, TP53, CHK2
and PTEN account for many, but not all, multiple-case breast
and ovarian cancer families. The histone acetyltransferase gene
EP300 may function as a tumour suppressor gene because it is
sometimes somatically mutated in breast, colorectal, gastric and
pancreatic cancers, and is located on a region of chromosome
22 that frequently undergoes loss of heterozygosity in many
cancer types. We hypothesized that germline mutations in
EP300  may account for some breast cancer families that
include cases of gastric, pancreatic and/or colorectal cancer.
Methods We screened the entire coding region of EP300 for
mutations in the youngest affected members of 23 non-BRCA1/
BRCA2 breast cancer families with at least one confirmed case
of gastric, pancreatic and/or colorectal cancer. These families
were ascertained in Australia through the Kathleen Cuningham
Foundation Consortium for Research into Familial Breast
Cancer.
Results Denaturing HPLC analysis identified a heterozygous
alteration at codon 211, specifically a GGC to AGC (glycine to
serine) alteration, in two individuals. This conservative amino
acid change was not within any known functional domains of
EP300. The frequency of the Ser211 variant did not differ
significanlty between a series of 352 breast cancer patients
(4.0%) and 254 control individuals (2.8%; P = 0.5).
Conclusion The present study does not support a major role for
EP300 mutations in breast and ovarian cancer families with a
history of gastric, pancreatic and/or colorectal cancer.
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Introduction
Pathogenic mutations in BRCA1 and BRCA2 account for
the majority of but not all multiple-case breast cancer fami-
lies that include members with ovarian cancer or male
breast cancer. Among families with four or more female
cases of breast cancer, almost 70% may be due to other
predisposition genes [1]. Because there is a plethora of
plausible breast cancer susceptibility candidates, any
approach to their identification must be focused. Tumour
suppressor genes that are known to be somatically inacti-
vated in breast cancers are particularly attractive candi-
dates and warrant close scrutiny. One such gene is EP300,
which is a member of the histone acetyltransferase group
of proteins. Its encoded protein, EP300, has been shown
to regulate transcription through chromatin remodelling
and by acting as a transcriptional coactivator [2]. It has
been speculated that EP300 may play a central role in reg-
ulating responses to signals that induce growth or differen-
tiation [3].
Several lines of evidence suggest that EP300 may function
as a tumour suppressor. EP300 is a target for adenoviral
E1A oncoprotein, the binding of which has been reported
to be associated with malignant transformation. The gene
is located on chromosome 22q, which is a region that
exhibits frequent loss of heterozygosity in a variety of can-
cer types, including breast, ovarian, colorectal, gastric and
pancreatic cancers [4-11]. Muraoka and coworkers [12]
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reported somatic mis-sense alterations in EP300 in one of
27 colorectal cancers and in one of two gastric cancers.
Subsequently, Gayther and coworkers [13] identified six
truncating mutations in a study of 193 ovarian, breast,
colorectal, pancreatic, lung and brain tumours. Two of
these mutations were detected in primary breast and color-
ectal cancers, and four were detected in breast, colorectal
and pancreatic cancer cell lines. More recently, we identi-
fied inactivating mutations in EP300 in approximately 25%
of colorectal cancer cell lines [14]. In addition to epithelial
malignancies, EP300 has been implicated in the develop-
ment of acute myeloid leukaemia, in which where transloca-
tions involving fusion of EP300 with the monocytic
leukaemia zinc finger protein have occasionally been
observed [15-17]. These data, coupled with the known
involvement of EP300 in a wide range of cellular processes
that are associated with malignancy, strongly suggest that
it may be a tumour suppressor.
It is not known whether germline alterations in EP300 are
involved in any cancer predisposition syndrome and, with
so few somatic alterations reported, it would be difficult to
predict the clinical features of such a syndrome. Neverthe-
less, we postulated that, in addition to breast cancer, germ-
line mutations in EP300  may predispose to colorectal
cancer because somatic mutations have previously been
described in primary colorectal cancers [12,13] and trun-
cating mutations were identified in four of 17 cancer cell
lines [14]. In addition, pancreatic and gastric cancers may
also be a feature of such families because mutations have
been described in pancreatic cell lines [13] and somatic
missense alterations have been observed in one out of two
primary gastric tumours studied [12].
EP300 is a large gene spanning approximately 90 kilo-
bases on chromosome 22q13.2; it encodes a 2414 amino
acid protein with a molecular weight of approximately 260
kDa. The 8.6 kilobase mRNA transcript is encoded in 31
exons, with 5' and 3' noncoding regions of 778 base pairs
and 1117 base pairs, respectively. Analysis of cancer cell
lines suggests that inactivation of EP300 occurs predomi-
nantly as a result of protein truncating mutations (frame
shift and single nucleotide insertions/deletions) [14]. In
order to investigate the role played by germline mutations
in EP300 in breast cancer predisposition, we undertook a
mutation analysis of all 31 coding exons of EP300 among
23 multiple-case breast cancer families, which included
cases of pancreatic, gastric and/or colorectal cancer.
Methods
Multiple-case breast cancer families
Multiple-case breast cancer families with at least one case
of pancreatic, gastric and/or colorectal cancer were ascer-
tained through the Kathleen Cuningham Foundation Con-
sortium for Research into Familial Breast Cancer
(kConFab; http://www.kconfab.org/). Confirmation of can-
cer diagnosis was obtained from pathology reports or med-
ical records, and was available for 61% of breast cancer
cases and for at least one case of pancreatic, gastric and/
or colorectal cancer. Twenty-three multiple-case families
were identified, which included at least one case of pancre-
atic cancer (three families), gastric cancer (nine families)
and/or colorectal cancer (17 families; Table 1).
The kConFab entrance criteria for families without a known
mutation in BRCA1 or BRCA2 are four or more cases of
breast or ovarian cancer in the same or adjacent genera-
tions (or two or more if one has 'high risk' features, such as
breast cancer diagnosis at age under 40 years, male breast
cancer, bilateral breast cancer, or ovarian and breast can-
cer in the same woman). All of the families were tested by
diagnostic laboratories for mutations in BRCA1  and
BRCA2 by a variety of means, including single-stranded
conformational polymorphism/heteroduplex analysis, pro-
tein truncation tests, chemical mismatch cleavage and/or
allele specific oligonucleotide hybridization. The overall
sensitivity of these tests for detecting mutations in BRCA1
and BRCA2 is estimated at 80%. In addition, nine out of 23
index cases were found to be mutation negative after full
sequencing of BRCA1 and/or BRCA2.
The index case, defined as the youngest available breast
cancer patient, was identified from each of these families
for mutation analysis (Table 1). In some families, such as
those of proband 0017 and 1018, there was no younger
case with breast, colorectal, gastric or pancreatic cancer
available for testing.
Breast cancer cases and controls
The frequency of any germline variants was assessed in a
series of breast cancer cases and control individuals. The
352 breast cancer patients were recruited in a hospital-
based case–control study of breast cancer predisposing
genes, carried out at breast clinics in the Wessex region of
southern England. They were selected on the basis of age
at onset under 40 years (203 cases), a family history of
breast cancer (defined as two or more cases of breast can-
cer in a first-degree or second-degree female relative) irre-
spective of age at onset (105 cases), or bilateral breast
cancer diagnosed after 39 years of age irrespective of fam-
ily history (44 cases). All breast cancer patients were sys-
tematically identified through breast clinics in the Wessex
region of southern England, as described previously
[18,19]. The age range of the breast cancer patients was
19–79 years, with a mean age of 38 years. The control indi-
viduals were representative of the population from which
the patients arose, and included 254 Caucasian female vol-
unteers who either were staff at the Princess Anne Hospi-
tal, Southampton, UK or were patients attending for non-
neoplastic disease conditions. The age range of the controlAvailable online http://breast-cancer-research.com/content/6/4/R366
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individuals was 18–84 years, with a mean age of 39 years.
For all groups normal genomic DNA was prepared from
blood lymphocytes. Comparisons of genotype frequencies
were analyzed using Fisher's exact test using the relevant 2
× 2 contingency tables. All statistical calculations were
two-sided and performed using InStat version 3.01 (Graph-
Pad Software Inc., San Diego, CA, USA). P < 0.05 was
considered statistically significant.
Mutation analysis
Normal genomic DNA was prepared from blood lym-
phocytes for all index cases and control individuals. All 31
coding exons of EP300, including splice junctions, were
amplified from genomic DNA using primers binding to com-
plementary intronic regions (Table 2). Because of their
larger size, exons 2, 14 and 31 were amplified in overlap-
ping segments using primers complementary to exonic
sequences.
PCR was performed in a reaction volume of 20 µl contain-
ing 50 ng genomic DNA, 25 ng of each primer, 10× reac-
tion buffer, 1 µl of a nucleotide mix (4 mmol/l each of dCTP,
dTTP, dGTP and dATP) and 0.5 µ Taq DNA polymerase
(AmplitaqGold; Perkin-Elmer, Branchbury, NJ, USA). The
standard program used for PCR amplification was as fol-
lows: one initial denaturation step of 94°C for 5 min, 35
cycles of 30 s denaturation at 94°C, 30 s of annealing (50–
60°C), and 60 s extension at 72°C, followed by a final elon-
gation cycle at 72°C for 5 min. All PCR products were
checked for purity on 2% agarose gels. Before denaturing
HPLC (DHPLC) analysis, the PCR products were dena-
tured at 95°C for 5 min and gradually cooled to 65°C at a
Table 1
Features of the probands and their families analyzed for EP300 germline mutations
Number of tumours in the family1
Proband Proband tumour site Proband age at onset (years) Breast Ovary Bowel Pancreatic Stomach Other
0011 br 32 8 0 1 0 2 0
0017 br 70 3 0 0 0 1 0
0187 br/bil 28/39 7 0 1 0 0 0
0318 br/ov 41/46 7 2 1 0 1 1
0329 br 43 3 0 1 0 0 1
0342 br 41 2 0 0 0 1 1
0458 br 46 4 0 0 0 1 3
0580 br 44 5 1 2 0 0 1
0894 br 45 5 0 0 1 0 1
0933 br 50 4 0 0 1 0 1
0990 br 42 4 0 1 0 0 2
1018 br 66 5 0 3 0 1 8
1115 br 49 6 1 1 0 3 4
1279 br 41 4 0 2 0 0 4
1566 br 53 4 0 1 0 1 4
1853 br/bil 43/47 2 0 2 0 0 1
1890 br/stom 21/49 2 0 6 0 0 5
1934 br 49 4 0 3 0 0 3
2033 br/stom/th 37/58/59 3 0 0 0 1 1
2220 br 29 5 0 1 1 0 4
2263 br 38 4 0 4 0 0 1
4734 br 49 6 0 2 0 0 7
0001 br 37 2 0 1 0 0 0
1The number of tumors includes proband's tumors. bil, bilateral breast cancer; br, breast cancer; ov, ovarian cancer; stom, stomach cancer; th, 
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Table 2
Primers used to amplify exons and splice junctions of EP300
Exon Forward1 Reverse Product size (base pairs) Predicted melt temperature (°C)2
1 Atttcctgaggattctggtt cgcaccgagtagaaaagat 202 57,62
2a gacctttgtcttttcccttt accctgatttggtccacta 372 60
2b aggcaggcttgacttctc gcacacaaaccaaaactgta 372 60
3 ttgcttattttgttttcttttg atgccagtttgaaaacaagt 254 52,57
4 agcacattatgactcctaccatt acagtaaccctgtgggtcc 333 57,62
5 cattaacctgctcttgaaaaa actggtgagactttaaaactt 210 57
6 ttctcaccagcattaatttgt tgacacaaccaataccatgt 335 5560
7 tgtctcctgttatttcattttg tgtaatgtgacccagggtat 161 57
8 aactatttggtgaccccttt gaatgagacgtgtccacaat 193 54,59
9 aaatgctgacatgatattacagtgg ccacaacaggttcaatcttgg 212 58
10 tgttacctggtggtagttcc caaacagaaatataacaaaaacca 266 58,53
11 aatattttgtggggtttgtg gtacaccggggattctttta 215 58,53
12 aatttcacaaaggcattcag aggtaaaggccaaagagatt 196 55,60
13 gaagcagtttggtgatttgt tgaaaaatccacttatgagaca 201 55,60
14a tgttctgaattgctgtcttg ccttggagggggatgtag 311 56,61
14b acagtcccaggctctaca atgattctgcctaaatccaa 231 62,57
15 gcgtgtgtctcacctacttcc ggtcatatacatatcaaacagtaattg 257 60
16 tgagaaagggtgttcagatt tcttcagctacctccagaac 261 5358
17 tggaactaatttcaaatgccc ccaccaaatacttacagggattc 169 54,59
18 ggatgatactccatctcccg tcccagaaaagttaaagtcaaatc 350 57
19 tgtccttaaggcctctgtgc cactccctggacatgtggac 190 60
20 acagttcaccccagtatggc tgtgcataatcactggacaaca 174 59
21 tcctttggttagaacagcag tcaagagaatgaaagggaaa 196 56
22 attgcaagttttcatttggt ttccagagaaagtaacaacg 171 58
23 cggtttatctaagttgtgtaagca ggcttcagataagttttgcca 160 54
24 aacaacagtaaatttgcacctca tttggatccacgaggagag 241 54,59
25 gtggttcccccaccatct cggagctagccactgtgag 205 60
26 tttcctcttcatttctcttca ccagaatgccatgctagttaaa 239 55
27 ttccttaatgttctttctctttg ttccagatctattgtcagca 242 54,59
28 catgcatgttttcacaggat agaagtttcaaaggaaactcaatg 213 57
29 tttcttgtctcctttgtgctt agaaatcttgccgtttttc 236 59
30 gaggccctgtctcaaaaa ctcctccttcccacaacc 350 62
31a gagagtttacgtgcacctcct ccattggttttccgtttg 303 61
31b atcctgccagaagatgaag gttggtgtcgttggagtg 309 62
31c gtggttgggcagcaacag ctgctctctgaatctgcatt 289 63
31d ctcagccaccccttccag ttcaaaggttgaccatgc 337 57,62
31 gccagccatgatgtcagt gcatggtaggtggctgta 320 62
31f gctgttggctgcattcat gatgtctcggaattgtgaag 310 62
31g ctcagcagatgaacatgaac catctgttgctgaaggagtc 314 61
31h aggcaggtgccagtctac agctaccagtccaggatg 305 62
31i ctcagccttctccacacc gctcccaaaatactacaagg 273 61
1All primer sequences are shown in the 5' to 3' direction. 2The optimal melting temperature for each PCR fragment were calculated using the 
DHPLC Melt program http://insertion.stanford.edu/melt.html. Where more than one optimal temperature was predicted, both were used in the 
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rate of 1°C/min. The optimal melting temperatures for each
PCR fragment are shown in Table 2 and were calculated
using the DHPLC Melt program http://insertion.stan
ford.edu/melt.html.
Samples of 4 µl were then analyzed on a Varian-Helix
DHPLC system (Varian, Inc., Palo Alto, CA, USA) using a
Helix DNA 75 mm × 3.0 mm column. Analysis was carried
out at the recommended melt temperature using the univer-
sal elution conditions recommended by the manufacturer.
Briefly, DNA was eluted at a flow rate of 0.45 ml/min with a
total running time of 8 min and 50 s in a linear acetonitrile
gradient made by mixing buffer A (0.1 mmol/l triethylammo-
nium acetate, 0.1 mmol/l EDTA) with buffer B (0.1 mol/l tri-
ethylammonium acetate, 25% acetonitrile, 0.1 nmol/l
EDTA). Initially, the samples were eluted for 30 s with a
constant buffer B content of 45%. This was followed by a
5 min 30 s period during which the buffer B concentration
increased from 45% to 68%. The buffer B concentration
was then held at 68% for 1 min and thereafter decreased
to 45% for a further 1 min and 50 s. Samples with varia-
tions in elution profiles were identified using the Varian Star
Reviewer software package.
For each variant elution profile, the genomic DNA was re-
amplified with the DHPLC primers and sequenced using
the Big-Dye sequencing chemistry (Perkin-Elmer).
Results
DHPLC analysis of the youngest available member affected
with breast cancer from each of the families identified only
two with variations in elution profiles, both of which were in
exon 2b of EP300 (Fig. 1). Individual 0017 had breast can-
cer (age at onset 70 years) and a family history of female
breast cancer (three cases) and gastric cancer (one case;
age at onset 45 years). Individual 0318 had breast and
ovarian cancer (age at onset 41 and 46 years, respectively)
and a family history of biliary tract cancer (age at onset 80
years), breast cancer (seven cases), ovarian cancer (two
cases), bowel cancer (age at onset 73 years) and gastric
cancer (age at onset 70 years; Table 1). Sequencing
revealed that both individuals harboured a heterozygous
G1830A substitution (NM_001429; gi:4557556) in codon
211, resulting in a glycine to serine substitution.
To further investigate the possible role of this variant in can-
cer predisposition, we conducted a case–control study
using a UK-based series of 352 breast cancer patients and
254 control individuals. The frequency of heterozygous car-
riers of the Ser211 variant was determined by DHPLC anal-
ysis. We did not find any significant difference in the
frequency of carriers of the Ser211 variant between the
patients (14/352 [4.0%]) and control individuals (7/254
[2.8%]; P = 0.5).
Discussion
The EP300 gene is located at the centre of a region of fre-
quent loss of heterozygosity in breast and ovarian cancer,
and has recently been implicated as a tumour suppressor
gene by the identification of somatic alterations in breast,
colon, pancreatic and gastric primary tumours and cell
lines. As such, we reasoned that EP300 was a plausible
susceptibility gene in multiple-case breast and ovarian can-
cer families with additional cases of gastric, pancreatic
and/or colorectal cancer. However, in the present study we
identified only one coding variant of EP300 in two out of 23
such multiple-case cancer families. This glycine to serine
substitution is unlikely to have any detrimental impact on
the activity of EP300 because both are small, neutral and
uncharged amino acids, and the substitution is located in a
region of the EP300 protein with no recognized functional
domain. The polymorphism has no effect on exonic splicing
enhancers as predicted by the ESEfinder program http://
exon.cshl.org/cgi-bin/ESE. Furthermore, the fact that no
significant difference was detected in the frequency of this
variant among 254 control individuals and 352 breast can-
cer cases further suggests that it represents a nonpatho-
genic polymorphism. Given that DHPLC is a robust and
sensitive screening technique, we consider it unlikely that
we missed any pathogenic variants among the 23 index
cases analyzed. In particular, we analyzed each PCR frag-
ment at all the temperatures recommended by the DHPLC
Melt algorithm, and under these conditions DHPLC has
been reported to have a sensitivity of 99.4% [20].
In the present study we restricted our analysis to non-
BRCA1/BRCA2 mutation families with a family history that
included gastric, pancreatic and/or colorectal cancer
because somatic mutations have been identified in EP300
in these cancer types. However, it is possible that this may
not be a reliable indicator of a familial cancer phenotype
Figure 1
Denaturing HPLC (DHPLC) elution profile of EP300 exon 2b run at  60°C Denaturing HPLC (DHPLC) elution profile of EP300 exon 2b run at 
60°C. Individuals 0318 (red trace) and 0017 (green trace) exhibit two 
distinct peaks compared with control individual 1115 (blue track) with 
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generated by germline mutations in EP300, given that our
selection criteria were based on identification of mutations
in only a small number of cancers [12,13]. Furthermore, we
tested only 23 probands and can only conclude that germ-
line EP300 mutations are not common in this sample set.
Conclusion
Based on the spectrum of mutations observed in sporadic
tumors, we hypothesized that germline mutations in EP300
may account for some breast cancer families that contain
cases of gastric, pancreatic and/or colorectal cancer. Anal-
ysis of 23 probands suggests that germline EP300 muta-
tions do not play a major role in breast cancer families with
a history of these other cancer types. However, the study
does not entirely exclude the possibility that EP300 may
represent a breast cancer susceptibility gene, and more
extensive studies of non-BRCA1/BRCA2  breast cancer
families, irrespective of a history of other cancer types, are
warranted.
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